Tivantinib is their lead product, according to their website
Lead Product
ArQule has advanced into Phase 3 clinical development with its lead product, tivantinib (ARQ 197), an orally available, small molecule that inhibits the c-Met receptor tyrosine kinase without competing with ATP for its binding to this kinase.